Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: A randomized Phase II study comparing the incidence of peripheral neuropathy

Breast Cancer Research and Treatment

Volumn 140, Issue 2, 2013, Pages 341-351

  Vahdat, Linda T ^a   Garcia, Agustin A ^b   Vogel, Charles ^c   Pellegrino, Christine ^d   Lindquist, Deborah L ^e   Iannotti, Nicholas ^f   Gopalakrishna, Prashanth ^g   Sparano, Joseph A ^d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e US Oncology   (United States)

^f Hematology Oncology Assoc of the Treasure Coast   (United States)

^g EISAI CO LTD   (Japan)

Author keywords

Eribulin mesylate; Ixabepilone; Metastatic breast cancer; Peripheral neuropathy

Indexed keywords

ERIBULIN; IXABEPILONE; TAXANE DERIVATIVE; EPOTHILONE DERIVATIVE; FURAN DERIVATIVE; KETONE;

ADULT; ALLODYNIA; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST METASTASIS; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DEMYELINATING POLYNEUROPATHY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; HYPERESTHESIA; INCIDENCE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PALLANESTHESIA; PARESTHESIA; PERIPHERAL MOTOR NEUROPATHY; PERIPHERAL NEUROPATHY; PERIPHERAL SENSORIMOTOR NEUROPATHY; PERIPHERAL SENSORY NEUROPATHY; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VOMITING; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; MIDDLE AGED; NEOPLASM METASTASIS; PATHOLOGY; SURVIVAL RATE;

ADULT; BREAST NEOPLASMS; EPOTHILONES; FEMALE; FURANS; HUMANS; KETONES; MIDDLE AGED; NEOPLASM METASTASIS; PERIPHERAL NERVOUS SYSTEM DISEASES; SURVIVAL RATE;

EID: 84881474908     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2574-2     Document Type: Article

References (21)

1. Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA (2004) Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 64:5760-5766
2. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsky BM, Palme MH, Habgood GJ, Singer LA, Dipietro LV, Wang Y, Chen JJ, Quincy DA, Davis A, Yoshimatsu K, Kishi Y, Yu MJ, Littlefield BA (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61:1013-1021
3. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086-1095
4. Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA (2008) Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 7:2003-2011
5. Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA (2010) Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49:1331-1337
6. Towle MJ, Salvato KA, Wels BF, Aalfs KK, Zheng W, Seletsky BM, Zhu X, Lewis BM, Kishi Y, Yu MJ, Littlefield BA (2011) Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 71:496-505
7. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study. Lancet 377:914-923
8. Eisai Inc (2012) Halaven prescribing information. http://www.halaven.com/ . Accessed 1 Feb 2013
9. Pachman DR, Barton DL, Watson JC, Loprinzi CL (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90:377-387
10. Speck RM, Demichele A, Farrar JT, Hennessy S, Mao JJ, Stineman MG, Barg FK (2012) Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Support Care Cancer 20:2433-2439
11. Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O'Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL (2009) Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27:2954-2961
12. Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA (2010) Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 28:3922-3928
13. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA (2001) BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429-1437
14. Bristol-Myers Squibb Company (2011) IXEMPRA™ Kit (ixabepilone) for Injection prescribing information. http://packageinserts.bms.com/pi/pi-ixempra. pdf. Accessed 1 Feb 2013
15. Thomas E, Tabernero J, Fornier M, Conté P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D, Martin M (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25:3399-3406
16. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN (2007) Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407-3414
17. Roché H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J, Kerbrat P, Delord JP, Vahdat L, Peck R, Lebwohl D, Ezzeddine R, Curé H (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 25:3415-3420
18. Rugo HS, Barry W, Moreno-Aspitia A, Lyss AP, Cirrincione C, Mayer EL, Naughton M, Layman RM, Carey LA, Somer RA, Perez EA, Hudis C, Winer EP (2012) CALGB 40502/NCCTG N063H: Randomized Phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 30:CRA1002
19. Wozniak KM, Nomoto K, Lapidus RG, Wu Y, Carozzi V, Cavaletti G, Hayakawa K, Hosokawa S, Towle MJ, Littlefield BA, Slusher BS (2011) Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res 71:3952-3962
20. LaPointe NE, Wilson L, Feinstein SC, Jordan M (2011) Effects of eribulin, vincristine, paclitaxel, and ixabepilone on kinesin-driven microtubule gliding. Presented at Society for Neuroscience National Meeting, Washington DC, USA, 12-16 Nov 2011, poster 367.01
21. Vahdat LT, Thomas ES, Roché HH, Hortobagyi GN, Sparano JA, Yelle L, Fornier MN, Martin M, Bunnell CA, Mukhopadhyay P, Peck RA, Perez EA (2012) Ixabepilone-associated peripheral neuropathy: data from across the Phase II and III clinical trials. Support Care Cancer 20:2661-2668